Brief: Urogen Pharma Ltd Says Results Of The First Post-Commercial Utilization Review Of Jelmyto Provide New Evidence That Reinforces Its Efficacy And Safety In Patients With Low-Grade Upper Tract Urothelial Cancer
11/01/2023 14:03
Jan 11 (Reuters) - Urogen Pharma Ltd UR8.F :
* RESULTS OF THE FIRST POST-COMMERCIAL UTILIZATION REVIEW OF
JELMYTO PROVIDE NEW EVIDENCE THAT REINFORCES ITS EFFICACY AND
SAFETY IN PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER
Source text for Eikon: ID:nBw87GYlNa
Further company coverage: UR8.F
((reuters.briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors